Anti-M üllerian Hormone Levels and Risk of Cancer: A Systematic Review

Anti-M üllerian hormone (AMH) is considered to be a suitable marker for the assessment of ovarian function in women after cancer therapy, given its role in ovarian follicle development.1 Based on experimental research, it has been suggested that AMH is a potential therapeutic agent for cancer.2–4 In viv o and in vitro studies showed that administration of AMH induced apoptosis and inhibited tumor cell growth in models for ovarian5, breast6,7 and prostate7,8 cancer. The involvement of AMH in processes like cell proliferation and apoptosis, raises the question whether AMH might also inhibit tumor dev elopment, especially as many different tissues are potentially responsive to AMH because of expression of the AMH type 2 receptor (AMHR2).

Source: Maturitas - March 8, 2020 Category: Primary Care Authors: Ren ée M.G. Verdiesen, Carla H. van Gils, Yvonne T. van der Schouw, N. Charlotte Onland-Moret Source Type: research